DDInter1371 DDInter492
Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth in malnourished or underdeveloped patients. Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. The uncontrolled misuse of oxymetholone can lead to a large variety of detrimental effects, the most often reported of which are cardiovascular events. In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
Deflazacort {u} may cause a minor interaction that can limit clinical effects when taken with {v} Isoniazid
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esterified estrogens
Deflazacort {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Cinoxacin
Deflazacort {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Deflazacort may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Deflazacort may lead to a major life threatening interaction when taken with Cinoxacin
Deflazacort may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live